Related Experiment Videos
Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor
J L Floiras1, K Hacene, F Turpin
1Department of Radiotherapy, Centre René Huguenin, St-Cloud, France.
The International Journal of Biological Markers
|July 7, 2000
Abstract:
The impact of ER levels on the response to tamoxifen was evaluated in 1,623 postmenopausal primary breast cancer patients treated at our center (median follow-up 8.2 years). In patients receiving adjuvant tamoxifen a significantly longer disease-free survival (DFS) was observed when ER levels were elevated (p<0.00001). Very high ER (>424 fmol/mg protein) appeared to be detrimental in node-negative patients not treated with tamoxifen.